Landiolol - AOP Orphan Pharmaceuticals

Drug Profile

Landiolol - AOP Orphan Pharmaceuticals

Alternative Names: AOP200704; LDLL600; Rapibloc

Latest Information Update: 13 Jul 2016

Price : $50

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Arrhythmias

Most Recent Events

  • 11 Jul 2016 Registered for Arrhythmias in European Union (IV)
  • 28 Mar 2016 AOP Orphan Pharmaceuticals completes a phase II trial in Arrhythmias (In elderly) in Austria (IV) (EudraCT2014-001905-42)
  • 23 Oct 2014 Phase-II clinical trials in Arrhythmias (In the elderly) in Austria (IV) (EudraCT2014-001905-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top